341 related articles for article (PubMed ID: 30835950)
1. Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab.
Stone JH; Tuckwell K; Dimonaco S; Klearman M; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Schulze-Koops H; Schett G; Spiera R; Unizony SH; Collinson N
Arthritis Rheumatol; 2019 Aug; 71(8):1329-1338. PubMed ID: 30835950
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.
Strand V; Dimonaco S; Tuckwell K; Klearman M; Collinson N; Stone JH
Arthritis Res Ther; 2019 Feb; 21(1):64. PubMed ID: 30786937
[TBL] [Abstract][Full Text] [Related]
3. Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial.
Spiera R; Unizony SH; Bao M; Luder Y; Han J; Pavlov A; Stone JH
Semin Arthritis Rheum; 2021 Apr; 51(2):469-476. PubMed ID: 33784598
[TBL] [Abstract][Full Text] [Related]
4. New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension.
Stone JH; Spotswood H; Unizony SH; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Spiera R; Bao M
Rheumatology (Oxford); 2022 Jul; 61(7):2915-2922. PubMed ID: 34718434
[TBL] [Abstract][Full Text] [Related]
5. Treatment failure in giant cell arteritis.
Unizony SH; Bao M; Han J; Luder Y; Pavlov A; Stone JH
Ann Rheum Dis; 2021 Nov; 80(11):1467-1474. PubMed ID: 34049857
[TBL] [Abstract][Full Text] [Related]
6. Trial of Tocilizumab in Giant-Cell Arteritis.
Stone JH; Tuckwell K; Dimonaco S; Klearman M; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Schett G; Schulze-Koops H; Spiera R; Unizony SH; Collinson N
N Engl J Med; 2017 Jul; 377(4):317-328. PubMed ID: 28745999
[TBL] [Abstract][Full Text] [Related]
7. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.
Unizony S; Arias-Urdaneta L; Miloslavsky E; Arvikar S; Khosroshahi A; Keroack B; Stone JR; Stone JH
Arthritis Care Res (Hoboken); 2012 Nov; 64(11):1720-9. PubMed ID: 22674883
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations.
Unizony S; McCulley TJ; Spiera R; Pei J; Sidiropoulos PN; Best JH; Birchwood C; Pavlov A; Stone JH
Arthritis Res Ther; 2021 Jan; 23(1):8. PubMed ID: 33407817
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study.
Samson M; Devilliers H; Ly KH; Maurier F; Bienvenu B; Terrier B; Charles P; Guillevin L; Besancenot JF; Liozon E; Fauchais AL; Loffroy R; Binquet C; Audia S; Seror R; Mariette X; Bonnotte B
Eur J Intern Med; 2018 Nov; 57():96-104. PubMed ID: 30054122
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period.
Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S;
Mod Rheumatol; 2018 Jan; 28(1):76-84. PubMed ID: 28622048
[TBL] [Abstract][Full Text] [Related]
11. Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study.
Schmitt C; Brockwell L; Giraudon M; Zucchetto M; Christ L; Bannert B; Daikeler T; Villiger PM
Arthritis Res Ther; 2022 Jun; 24(1):133. PubMed ID: 35659282
[TBL] [Abstract][Full Text] [Related]
12. The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis-study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study.
Kreis L; Dejaco C; Schmidt WA; Németh R; Venhoff N; Schäfer VS
Trials; 2024 Jan; 25(1):56. PubMed ID: 38225579
[TBL] [Abstract][Full Text] [Related]
13. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
Burmester GR; Buttgereit F; Bernasconi C; Álvaro-Gracia JM; Castro N; Dougados M; Gabay C; van Laar JM; Nebesky JM; Pethoe-Schramm A; Salvarani C; Donath MY; John MR;
Lancet; 2020 Jul; 396(10246):267-276. PubMed ID: 32711802
[TBL] [Abstract][Full Text] [Related]
14. Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial.
Devauchelle-Pensec V; Carvajal-Alegria G; Dernis E; Richez C; Truchetet ME; Wendling D; Toussirot E; Perdriger A; Gottenberg JE; Felten R; Fautrel BJ; Chiche L; Hilliquin P; Le Henaff C; Dervieux B; Direz G; Chary-Valckenaere I; Cornec D; Guellec D; Marhadour T; Nowak E; Saraux A
JAMA; 2022 Sep; 328(11):1053-1062. PubMed ID: 36125471
[TBL] [Abstract][Full Text] [Related]
15. Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials.
Verhoeven MM; de Hair MJ; Tekstra J; Bijlsma JW; van Laar JM; Pethoe-Schramm A; Borm ME; Ter Borg EJ; Linn-Rasker SP; Teitsma XM; Lafeber FP; Jacobs JW; Welsing PM
Ann Rheum Dis; 2019 Oct; 78(10):1333-1338. PubMed ID: 31196844
[TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis.
Reichenbach S; Adler S; Bonel H; Cullmann JL; Kuchen S; Bütikofer L; Seitz M; Villiger PM
Rheumatology (Oxford); 2018 Jun; 57(6):982-986. PubMed ID: 29529280
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
Villiger PM; Adler S; Kuchen S; Wermelinger F; Dan D; Fiege V; Bütikofer L; Seitz M; Reichenbach S
Lancet; 2016 May; 387(10031):1921-7. PubMed ID: 26952547
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients.
Loricera J; Blanco R; Hernández JL; Castañeda S; Mera A; Pérez-Pampín E; Peiró E; Humbría A; Calvo-Alén J; Aurrecoechea E; Narváez J; Sánchez-Andrade A; Vela P; Díez E; Mata C; Lluch P; Moll C; Hernández Í; Calvo-Río V; Ortiz-Sanjuán F; González-Vela C; Pina T; González-Gay MÁ
Semin Arthritis Rheum; 2015 Jun; 44(6):717-23. PubMed ID: 25697557
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice.
Calderón-Goercke M; Loricera J; Aldasoro V; Castañeda S; Villa I; Humbría A; Moriano C; Romero-Yuste S; Narváez J; Gómez-Arango C; Pérez-Pampín E; Melero R; Becerra-Fernández E; Revenga M; Álvarez-Rivas N; Galisteo C; Sivera F; Olivé-Marqués A; Álvarez Del Buergo M; Marena-Rojas L; Fernández-López C; Navarro F; Raya E; Galindez-Agirregoikoa E; Arca B; Solans-Laqué R; Conesa A; Hidalgo C; Vázquez C; Román-Ivorra JA; Lluch P; Manrique-Arija S; Vela P; De Miguel E; Torres-Martín C; Nieto JC; Ordas-Calvo C; Salgado-Pérez E; Luna-Gomez C; Toyos-Sáenz de Miera FJ; Fernández-Llanio N; García A; Larena C; Palmou-Fontana N; Calvo-Río V; Prieto-Peña D; González-Vela C; Corrales A; Varela-García M; Aurrecoechea E; Dos Santos R; García-Manzanares Á; Ortego N; Fernández S; Ortiz-Sanjuán F; Corteguera M; Hernández JL; González-Gay MÁ; Blanco R
Semin Arthritis Rheum; 2019 Aug; 49(1):126-135. PubMed ID: 30655091
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
Cid MC; Unizony SH; Blockmans D; Brouwer E; Dagna L; Dasgupta B; Hellmich B; Molloy E; Salvarani C; Trapnell BC; Warrington KJ; Wicks I; Samant M; Zhou T; Pupim L; Paolini JF;
Ann Rheum Dis; 2022 May; 81(5):653-661. PubMed ID: 35264321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
